InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.800 0.03 (3.90%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$382 Appendix 4G - Corporate Governance Statement 29 Aug 2016 9:14AM $0.690 $0.800 risen by 15.94%
$382 Annual report and full year financial results 29 Aug 2016 9:00AM $0.690 $0.800 risen by 15.94%
$382 New DEP drug delivery program initiated with AstraZeneca 28 Jul 2016 9:43AM $0.670 $0.800 risen by 19.40%
$382 Starpharma signs license for a VivaGel condom in China 21 Jul 2016 1:10PM $0.700 $0.800 risen by 14.29%
$382 Appendix 4C - Quarterly Cashflow Reoprt 14 Jul 2016 9:33AM $0.660 $0.800 risen by 21.21%
$382 Change in substantial holding 14 Jun 2016 8:13AM $0.755 $0.800 risen by 5.96%
$382 Starpharma's DEP eliminates cabazitaxel neutropenia 25 May 2016 10:13AM $0.700 $0.800 risen by 14.29%
$382 Change in Director's Interest Notice - R Thomas 19 May 2016 10:06AM $0.675 $0.800 risen by 18.52%
$382 Starpharma to present at ASX CEO Session 17 May 2016 12:01PM $0.695 $0.800 risen by 15.11%
$382 Australian Olympic Team taking Dual Protect VivaGel Condoms 16 May 2016 9:33AM $0.700 $0.800 risen by 14.29%
$382 VivaGel active against Zika virus 5 May 2016 10:50AM $0.645 $0.800 risen by 24.03%
$382 Appendix 4C - Quarterly Cashflow Report 28 Apr 2016 11:30AM $0.665 $0.800 risen by 20.30%
$382 Shareholder Update April 2016 13 Apr 2016 9:40AM $0.715 $0.800 risen by 11.89%
$382 Starpharma to present at Bio-Europe conference 5 Apr 2016 10:36AM $0.725 $0.800 risen by 10.34%
$382 DEP cabazitaxel shows complete, sustained tumour regression 4 Apr 2016 10:12AM $0.700 $0.800 risen by 14.29%
$382 Adama Licenses Starpharma's Priostar for Novel 2,4-D 17 Mar 2016 9:48AM $0.635 $0.800 risen by 25.98%
$382 Starpharma licences VivaGel BV to Aspen for ANZ 4 Mar 2016 10:15AM $0.637 $0.800 risen by 25.59%
$382 Change in substantial holding 24 Feb 2016 8:23AM $0.610 $0.800 risen by 31.15%
$382 Interim Report and Half-Year Financial Results 17 Feb 2016 12:38PM $0.565 $0.800 risen by 41.59%
$382 Targeted DEP shows sustained superior performance 2 Feb 2016 2:01PM $0.615 $0.800 risen by 30.08%
$382 Appendix 4C - Quarterly Cashflow Report 28 Jan 2016 9:53AM $0.635 $0.800 risen by 25.98%
$382 Change in Director's Interest Notice - Z Peach 27 Jan 2016 10:57AM $0.615 $0.800 risen by 30.08%
$382 Change in Director's Interest Notice - P Turvey 27 Jan 2016 10:53AM $0.615 $0.800 risen by 30.08%
$382 Change in Director's Interest Notice - J Fairley 27 Jan 2016 10:48AM $0.615 $0.800 risen by 30.08%
$382 Change in Director's Interest Notice - R Thomas 27 Jan 2016 10:45AM $0.615 $0.800 risen by 30.08%

601 - 625 of 887 results

Page 25 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.